All In Biotech

Drug Trial Radar · NCT03740737

Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-1)

A Randomized, Double-blind, Placebo-controlled, Parallel Groups, Multicenter Trial Investigating the Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Women Aged 18-34 Years Undergoing Assisted Reproductive Technology

Last checked: Nov 19, 2026Latest source record: Jan 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 579 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

579

Actual

Start

Oct 26, 2018

Primary completion

Nov 11, 2020

Study completion Nov 11, 2020

Sponsor

Lead sponsor
Ferring PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Nov 14, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 34 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial investigates the effects of FE 999049 compared to placebo.

Conditions

  • Infertility

Interventions

  • Follitropin deltaDrug

    FE 999049 was administered as single daily subcutaneous injections in the abdomen at a starting dose of 12 µg daily that was fixed for the first four stimulation days. Based on ovarian response, the dose could be adjusted by 3 µg, with dose increases implemented not more frequently than once every 2 days and dose decreases implemented per investigator's judgement. The minimum daily dose was 6 µg, and the maximum daily dose was 24 µg. Participants could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early ovarian hyperstimulation syndrome (OHSS) with the exception of gonadotropin-releasing hormone (GnRH) agonist for triggering of final follicular maturation, was not allowed.

  • PlaceboOther

    Placebo was administered as single daily subcutaneous injection dialed to the same value (dose) as FE 999049. Participants could be treated for a maximum of 20 days. Coasting, use of dopamine agonist or any other drug to prevent early OHSS with the exception of GnRH agonist for triggering of final follicular maturation, was not allowed.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative Ongoing Pregnancy Rate After the Fresh Cycle and Cryopreserved Cycles Initiated Within 12 Months From the Start of COSTime frame: 8-9 weeks after transfer (up to approximately 16 months after start of stimulation)

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Fertility Treatment Center

    Tempe, Arizona

  • HRC Fertility

    Encino, California

  • Center for Advanced Reproductive Services PC

    Farmington, Connecticut

  • Reproductive Associates of Delaware

    Newark, Delaware

  • Women's Medical Research Group, LLC

    Clearwater, Florida

  • Center for Reproductive Medicine

    Winter Park, Florida

  • Fertility Institute of Hawaii, INC

    Honolulu, Hawaii

  • Fertility Centers of Illinois (RH)

    Chicago, Illinois

  • InVia Fertility

    Hoffman Estates, Illinois

  • Boston IVF

    Waltham, Massachusetts

  • Mayo Clinic

    Rochester, Minnesota

  • Reproductive Endocrinology Associates of Charlotte (REACH) S. Corporation

    Charlotte, North Carolina

  • Carolina Conceptions

    Raleigh, North Carolina

  • Institute for Reproductive Health

    Cincinnati, Ohio

  • Abington Reproductive Medicine

    Abington, Pennsylvania

  • Main Line Fertility Center

    Bryn Mawr, Pennsylvania

  • Fertility Associates of Memphis, PLLC

    Memphis, Tennessee

  • Center for Assisted Reproduction

    Bedford, Texas

  • Houston Fertility Institute

    Houston, Texas

  • Center of Reproductive Medicine

    Webster, Texas

  • Utah Fertility Center

    Pleasant Grove, Utah

  • Eastern Virginia Medical School | EVMS Obstetrics & Gynecology

    Norfolk, Virginia

  • Seattle Reproductive Medicine WA

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.